Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of BVS857 in spinal and bulbar muscular atrophy
2013-002608-15Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2014
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in spinal and bulbar muscular atrophy (SBMA) comparing BVS857 with Placebo (2 arms). Primary endpoint: Safety and tolerability of BVS857. Started Feb 2014; status: completed.
02
Drugs
BVS857
03
Conditions
spinal and bulbar muscular atrophy (SBMA)
Beyond the preview
Go deeper on 2013-002608-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002608-15.